These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1794 related items for PubMed ID: 19558252

  • 1. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR.
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [Abstract] [Full Text] [Related]

  • 2. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine.
    Schwedt TJ, Hentz JG, Dodick DW.
    Cephalalgia; 2007 Jun; 27(6):528-34. PubMed ID: 17459081
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Role of botulinum toxin type A in the prophylactic treatment of migraine headaches.
    Chilson CN, Brown SJ.
    Ann Pharmacother; 2005 Dec; 39(12):2081-5. PubMed ID: 16264063
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.
    Petri S, Tölle T, Straube A, Pfaffenrath V, Stefenelli U, Ceballos-Baumann A, Dysport Migraine Study Group.
    Eur Neurol; 2009 Dec; 62(4):204-11. PubMed ID: 19622887
    [Abstract] [Full Text] [Related]

  • 15. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW.
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [Abstract] [Full Text] [Related]

  • 16. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.
    Jackson JL, Kuriyama A, Hayashino Y.
    JAMA; 2012 Apr 25; 307(16):1736-45. PubMed ID: 22535858
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
    Vitale S, Miller NR, Mejico LJ, Perry JD, Medura M, Freitag SK, Girkin C.
    Am J Ophthalmol; 2004 Jul 25; 138(1):18-32. PubMed ID: 15234278
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.